Myopia — commonly known as nearsightedness — is one of the fastest-growing health conditions worldwide. The World Health Organization projects that half of the global population will be myopic by 2050. What was once considered a minor inconvenience correctable with glasses is now understood to be a progressive eye disease: the higher the myopia, the greater the lifetime risk of retinal detachment, glaucoma, macular degeneration, and cataracts. At Amwell Eye Care, Dr. Adam Zhao offers evidence-based myopia management strategies designed to slow the progression of myopia in children and reduce their risk of serious eye disease in adulthood.
Myopia occurs when the eye grows too long from front to back, causing light to focus in front of the retina rather than directly on it. This results in clear near vision but blurry distance vision. Once myopia begins — typically between ages 6 and 14 — the eye continues to elongate and the prescription worsens, often rapidly, through the teenage years.
The primary drivers of myopia onset and progression are:
Standard glasses and contact lenses correct blurry vision but do nothing to slow the underlying axial elongation. Myopia management treatments actively work to reduce the rate at which the eye grows.
Each additional diopter of myopia meaningfully increases lifetime risk of serious eye disease:
Slowing progression by even one diopter significantly reduces these lifetime risks. This is why starting myopia management early — ideally at first diagnosis — makes such a meaningful difference to a child’s long-term eye health.
Dr. Zhao offers all major evidence-based myopia management treatments and will recommend the most appropriate option based on your child’s age, prescription, lifestyle, and rate of progression:
Orthokeratology is the gold standard myopia management treatment for most children and young adults. Custom-designed rigid gas-permeable lenses are worn overnight while sleeping. They gently and temporarily reshape the cornea so that the patient wakes up with clear, unaided vision throughout the day — no glasses or contacts needed during waking hours. Beyond the convenience, Ortho-K has strong clinical evidence for slowing axial elongation by 30–60% compared to standard glasses. It is FDA-cleared, reversible, and suitable for children as young as 6. Dr. Zhao has extensive experience fitting Ortho-K lenses and managing patients through their myopia control journey.
MiSight 1 day (CooperVision) is the first and only FDA-approved soft contact lens specifically indicated for myopia management in children aged 8–12 at initiation. These daily disposable lenses use a dual-focus ActivControl design — a central correction zone surrounded by treatment zones that reduce peripheral defocus, the signal thought to drive axial eye growth. Clinical trials show MiSight slows myopia progression by an average of 59% and axial elongation by 52% compared to standard single-vision lenses. MiSight is a particularly good option for younger children or those who are not yet ready for Ortho-K.
Beyond MiSight, several other myopia control soft lens designs are available including NaturalVue Multifocal and extended depth-of-focus lenses. Dr. Zhao will select the most appropriate design based on your child’s prescription, eye shape, and wearing preferences.
Low-dose atropine (0.01%–0.05%) eye drops are prescribed once daily at bedtime and have robust clinical evidence for slowing myopia progression by 50–60%. Unlike higher concentrations used historically, low-dose atropine causes minimal side effects — little to no pupil dilation, light sensitivity, or near blur. Atropine is often used as a standalone treatment in younger children not yet ready for contact lenses, or in combination with Ortho-K for patients with rapid progression.
For patients who are not yet ready for contact lenses or atropine, specialised spectacle lenses designed for myopia control — such as Essilor Stellest and DIMS (Defocus Incorporated Multiple Segments) lenses — are now available and provide meaningful slowing of progression while correcting vision through conventional glasses wear.
Evidence strongly supports at least 90 minutes of outdoor time per day as a protective factor against myopia onset and progression. Dr. Zhao provides personalised guidance on screen habits, reading distance, lighting, and outdoor activity as part of every myopia management plan.
Effective myopia management requires regular monitoring to track whether treatment is working and adjust the plan as needed. At Amwell Eye Care, Dr. Zhao uses:
Dr. Zhao recommends discussing myopia management for any child who:
Adults with progressing myopia may also benefit from certain management strategies. Dr. Zhao will assess each patient individually and discuss realistic expectations for slowing progression at any age.
Myopia management consultations and monitoring visits are covered under most vision insurance plans. Specialty contact lenses (Ortho-K, MiSight) and atropine drops involve additional costs that vary by treatment; our staff will outline all fees clearly before beginning any program. We accept VSP, EyeMed, Aetna, Blue Cross Blue Shield, and most major plans.
To schedule a myopia management consultation in Hillsborough, NJ, contact us online or call (908) 336-3886. Same-week appointments are often available.
The earlier myopia management begins, the greater the impact on your child’s long-term vision and eye health. Don’t wait for the prescription to get worse.